Product nameAnti-DR5 antibody
See all DR5 primary antibodies
DescriptionRabbit polyclonal to DR5
SpecificityDoes not cross react with DR4.
Tested applicationsSuitable for: IHC-P, WB, ICC/IFmore details
Species reactivityReacts with: Mouse, Human
- Whole cell lysate from HeLa cells
For information on sample preparation for western blot, please refer here.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.02% Sodium azide
Concentration information loading...
Immunizing Peptide (Blocking)
Our Abpromise guarantee covers the use of ab8416 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||Use a concentration of 5 µg/ml.|
|WB||Use a concentration of 2 µg/ml. Detects a band of approximately 60 kDa (predicted molecular weight: 47.8 kDa).Can be blocked with Human DR5 peptide (ab8449).|
|ICC/IF||Use a concentration of 5 µg/ml.|
FunctionReceptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. Essential for ER stress-induced apoptosis.
Tissue specificityWidely expressed in adult and fetal tissues; very highly expressed in tumor cell lines such as HeLaS3, K-562, HL-60, SW480, A-549 and G-361; highly expressed in heart, peripheral blood lymphocytes, liver, pancreas, spleen, thymus, prostate, ovary, uterus, placenta, testis, esophagus, stomach and throughout the intestinal tract; not detectable in brain.
Involvement in diseaseSquamous cell carcinoma of the head and neck
Sequence similaritiesContains 1 death domain.
Contains 3 TNFR-Cys repeats.
- Information by UniProt
- Fas like protein antibody
- Apoptosis inducing protein TRICK2A/2B antibody
- Apoptosis inducing receptor TRAIL R2 antibody
Immunohistochemical analysis of DR5 expression in mouse kidney tissue with ab8416 at 5µg/ml.
All lanes : Anti-DR5 antibody (ab8416) at 1/500 dilution
Lane 1 : HeLa whole cell lysate (7.5 µL (2 mg/mL) per well)
Lane 2 : K562 whole cell lysate (7.5 µL (2 mg/mL) per well)
Lysates/proteins at 15 µg per lane.
All lanes : anti-rabbit IgG-HRP conjugated secondary at 1/10000 dilution
Developed using the ECL technique.
Predicted band size: 47.8 kDa
Exposure time: 1 minute
Run in transfer buffer at 130V for 2 hours (or until the dye front is close to the bottom).
After transfer, wash membrane in 1xTBST.
Incubate the membrane with blocking buffer overnight at 4°C with gentle agitation.
Dilute ab8416 to recommended dilution in 10mL of blocking buffer. Incubate membrane with ab8416 for 1 hour at room temperature. Wash 3 times x 10 minutes in washing buffer with gentle agitation.
Dilute 1μL anti-rabbit IgG-HRP conjugated secondary in 10mL of blocking buffer to make a 1:10,000 dilution (can vary from 1:1,200 to 1:10,000). Incubate membrane for 1 hour at room temperature. Wash 3 times x 10 minutes in washing buffer with gentle agitation.
Running Buffer: 25mM Tris, 192 mM Glycine, 0.1% SDS.
Transfer Buffer: 20mM Tris, 150mM Glycine, 20% Methanol, 0.038% SDS.
Blocking Buffer: 5% non-fat dry milk, TBS.
Wash Buffer (TBST): 125 mM NaCl, 25mM Tris pH 8.0, 0.1% Tween-20.
Immunofluorescence of DR5 in HeLa cells with ab8416 at 20 μg/mL.
ab8416 at 5µg/ml staining DR5 in Hela cells by ICC/IF.
The image above is a xenograph of human cancer cells implanted into a nude mouse and allowed to grow for about three weeks. Notice only the human cancer cells expressed this antigen. This picture was kindly submitted as part of the reveiw by Dean Wilkie.
This product has been referenced in:
- Azhary JMK et al. Endoplasmic Reticulum Stress Activated by Androgen Enhances Apoptosis of Granulosa Cells via Induction of Death Receptor 5 in PCOS. Endocrinology 160:119-132 (2019). Read more (PubMed: 30423122) »
- Jones JD et al. Trabectedin Reduces Skeletal Prostate Cancer Tumor Size in Association with Effects on M2 Macrophages and Efferocytosis. Neoplasia 21:172-184 (2019). Read more (PubMed: 30591422) »